Coherus Oncology, Inc. announced on June 12, 2026, that its Audit Committee dismissed Ernst & Young LLP (EY) as its independent registered public accounting firm, effective immediately. The company' 's previous reports on consolidated financial statements for fiscal years 2024 and 2024 and the interim period through June 12, 2026, did not contain adverse or disclaimer of opinion. The company also appointed PricewaterhouseCoopers LLP (PwC) as its new independent registered public accounting firm for the fiscal year ending December 31, 2026, subject to standard acceptance procedures. Coherus Oncology, Inc. is a biotechnology company that develops and commercializes oncology products.